Debiopharm
Ulf Andersson serves as the Head of Preclinical Safety at Debiopharm since February 2022, bringing extensive experience from previous roles at AstraZeneca, where a longstanding career spanned from Associate Director to Senior Director in various capacities related to preclinical safety and toxicology. Prior to AstraZeneca, Ulf held a position as Associate Research Fellow at Pfizer, leading molecular toxicology efforts. Ulf's career began at Global Genomics AB and Tripep AB, focusing on gene expression profiling and the development of viral therapies, respectively. Ulf's educational background includes a postdoctoral degree in Cell and Molecular Biology from Northwestern University and a Ph.D. in Animal Physiology from Stockholm University.
This person is not in the org chart
This person is not in any teams
Debiopharm
2 followers
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.